Consequences of moderate hyperhomocysteinemia in the internal medicine;Význam mírné hyperhomocysteinémie pro vnitřní lékařství

Casopis Lekaru Ceskych

Volumn 143, Issue 6, 2004, Pages 367-374

  Žák, Aleš ^a   Zeman, M ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

B12 vitamins; B2; B6; Folic acid; Homocysteine; Hyperhomocysteinemia; Pharmoconutrition; Risk of cardiovascular diseases

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CHOLESTEROL; CYANOCOBALAMIN; ENZYME; FATTY ACID; FOLIC ACID; HOMOCYSTEINE; LIPOPROTEIN; METHIONINE; PROTEIN; PYRIDOXINE; RIBOFLAVIN;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CATALYSIS; CELL PROLIFERATION; CELL REGENERATION; CHEMICAL MODIFICATION; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE SEVERITY; HEREDITY; HYPERHOMOCYSTEINEMIA; INTERNAL MEDICINE; MORBIDITY; MORTALITY; NUTRITION; OXIDATIVE STRESS; RISK FACTOR; THROMBOGENESIS; VASCULAR ENDOTHELIUM; VITAMIN SUPPLEMENTATION;

CARDIOVASCULAR DISEASES; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; RISK FACTORS;

EID: 3042524986     PISSN: 00087335     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Boushey, C. J., Beresford, S. A., Omenn, G. S. et al.: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA, 1995, 274, s. 1049-1057.
2. D'Angelo, A., Selhub, J.: Homocysteine and thrombotic disease. Blood, 1997, 90, s. 1-11.
3. nd ed. Paris, Springer-Verlag France, 2002, 262 s.
4. Stehouwer, C. D. A., van Guldener, C.: Does Homocysteine cause hypertension? Clin. Chem. Lab. Med., 2003, 41, s. 1408-1411.
5. Giltay, E. J., Hoogeveen, E. K., Elbers J. M. H. et al.: Insulin resistance is associated with elevated plasma total homocysteine levels in healthy, non-obese subjects. Atherosclerosis, 1998, 139, s. 197-198.
6. Kožich, V., Kraus, J. P., Hyánek, J.: Homocystein, geny a vitaminy: Souvislost s kardiovaskulárními onemocnění mi a komplikacemi těhotenství. DMEV, 1999, 3, s. 113-120.
7. Riggs, K. M., Spiro, A., Tucker, K. et al.: Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the normative aging study. Am. J. Clin. Nutr., 1996, 63, s. 306-314.
8. Steegers-Theunissen, R. P., Boers, G. H., Trijbels, F. J. et al.: Maternal hyperhomocysteinemia: a risk factor for neural-tube defects? Metabolism, 1994, 43, s. 1475-1480.
9. Joosten, E., Lesaffre, E., Riezler, R. et al.: Is metabolic evidence for vitamin B12 and folate deficiency more frequent in elderly patients with Alzheimer's disease? J. Gerontol. Biol. Sci. Med. Sci., 1998, 52, s. M76 až M79.
10. Mangoni, A. A., Jackson, S. H. D.: Homocysteine and cardiovascular disease: current evidence and future prospects. Am. J. Med., 2002, 112, s. 556-565.
11. Jakubowski, H.: Homocysteine-thiolactone and S-nitroso-homocysteine mediate incorporation of homocysteine into protein in humans. Clin. Chem. Lab. Med., 2003, 41, s. 1462-1466.
12. th Ed. Philadelphia, Lea&Febiger, 1988, 30s.
13. Finkelstein, J. D.: Methionine metabolism in mammals. J. Nutr. Biochem., 1990, 1, s. 228-237.
14. Selhub, J.: Homocysteine metabolism. Annu. Rev. Nutr., 1999, 19, s. 217-246.
15. Brattström, L., Wilcken, D. E.: Homocysteine and cardiovascular disease: cause or effect? Am. J. Clin. Nutr., 2000, 73, s. 315-323.
16. Ueland, P. M., Hustad, S., Schneede, J. et al.: Biological and clinical implications of the MTHFR C677T polymorphism. Trends. Pharm. Sci., 2001, 22, s. 195-201.
17. Hustad, S., Ueland, P. M., Vollset, S. E. et al.: Riboflavin as a determinant of plasma total homocysteine: effect modification by the methylenetetrahydrofolate reductase C677T polymorphism. Clin. Chem., 2000, 46, s. 1065-1071.
18. Verhoef, P., Stamfer, M. J., Rimm, E. B.: Folate and coronary heart disease. Curr. Opin. Lipidol., 1998, 9, s. 17-22.
19. Meleady, R., Ueland, P. M., Blom, H. et al.: Thermolabile methylenetetrahydrofolate reductase, homocysteine, and cardiovascular disease risk: the European Concerted Action Project. Am. J. Clin. Nutr., 2003, 77, s. 63-70.
20. Geisel, J., Hübner, U., Bodis, M. et al.: The role of genetic factors in the development of hyperhomocysteinemia. Clin. Chem. Lab. Med., 2003, 41, s. 1427-1434.
21. Mudd, S. H., Levy, H. L., Skovby, F.: Disorders of transsulfuration. In: The metabolic and molecular basis of inherited disease. Scriver, C. R., Baudet, A. L., Sly, W. S. et al., eds., New York, McGraw-Hill Inc., 1995, s. 1279-1327.
22. DACH-LIGA Homocystein (German, Austrian, and Swiss Homocysteine Society): Consenus paper on rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic disease: guidelines and recommendations. Clin. Chem. Lab. Med., 2003, 41, s. 1392-1403.
23. Nygard, O., Vollset, S. E., Refsum, H. et al.: Total plasma homocysteine and cardiovascular risk profile: The Hordaland Homocysteine Study. JAMA, 1995, 274, s. 1526-1533.
24. Ueland, P. M., Refsum, H., Beresford, S. A. et al.: The controversy over homocysteine and cardiovascular risk. Am. J. Clin. Nutr., 2000, 72, s. 324-332.
25. Selhub, J., Jacques, P. F., Wilson, P. W. et al.: Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA, 1993, 270, s. 2693-2698.
26. Desouza, C., Keebler, M., McNamara D. B. et al.: Drugs affecting homocysteine metabolism. Drugs, 2002, 62, s. 605-616.
27. van Guldener, C., Stehouwer, C. D. A.: Homocysteine metabolism in renal disease. Clin. Chem. Lab. Med., 2003, 41, s. 1412-1417.
28. Buysschaert, M., Dramais, A.-S., Wallemacq, P. E. et al.: Hyperhomocysteinemia in type 2 diabetes. Diabetes Care, 2000, 23, s.1816-1822.
29. Egerton, W., Silberberg, J., Crooks, R. et al.: Serial measures of plasma homocyst(e)ine after acute myocardial infarction. Am. J. Cardiol., 1996, 77, s. 759-761.
30. Lindgren, A., Brattstrom, L., Norrving, B. et al.: Plasma homocysteine in the acute and convalescent phases after stroke. Stroke, 1995, 26, s. 795-800.
31. Jacques, P. F., Rosenberg, I. H., Rogers G. et al.: Serum total homocysteine concentrations in adolescent and adult Americans: results from the third National Health and Nutrition Examination Survey. Am. J. Clin. Nutr., 1999, 69, s. 482-489.
32. Das, U. N.: Folic acid says NO to vascular diseae. Nutrition, 2003, 19, s. 686-692.
33. Clarke, R., Lewington S., Donald, A. et al.: Underestimation of the importance of homocysteine as a risk factor for cardiovascular disease in epidemiologic studies. J. Cardiovasc. Risk., 2001, 8, s. 363-369.
34. den Heijer, M.: Hyperhomocysteinemia as a risk factor for venous thrombosis: an update of the current evidence. Clin. Chem. Lab. Med., 2003, 41, s. 1404-1407.
35. Clarke, R., Collins, R., Lewington S. et al.: Homocysteine and risk of ischaemic heart disease and stroke. A meta-analysis. JAMA, 2002, 288, s. 2015-2022.
36. Moustapha, A., Naso, A., Nahlawi, M. et al.: Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation, 1998, 97, s. 138-141.
37. Soinio, M., Marniemi, J., Laakso, M. et al.: Elevated plasma homocysteine levels is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus. Ann. Intern. Med., 2004, 140, s. 94-100.
38. Wald, D. S., Law, M., Morris J. K.: Homocysteine and cardiovascular disease: evidence on causality from a metaanalysis. Br. Med. J., 2002, 325, s. 1202-1208.
39. Ray, J. G.: Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch. Int. Med., 1998, 158, s. 2101 až 2106.
40. Fonseca, V. A., Fink, L. M., Kern, P. A.: Insulin sensitivity and plasma homocysteine concentrations in non-diabetic and normal weight subjects. Atherosclerosis, 2003, 167, s. 105-109.
41. Homocysteine Lowering Trialists' Collaboration: Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Br. Med. J., 1998, 3, s. 894-898.
42. Spence, J. D., Blake, C., Landry, A. et al.: Measurement of carotid plaque and effect vitamin therapy for total homocysteine. Clin. Chem. Lab. Med., 2003, 41, s. 1498-1504.
43. Vermeulen, E. G. J., Stehouwer, C. D. A., Twisk, J. W. R. et al.: Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet, 2000, 355, s. 517-522.
44. 6 on clical outcome after perctutaneous coronary intervention. The Swiss Heart Study: a randomized controlled trial. JAMA, 2002, 288, s. 973 až 979.
45. Schnyder, G., Roffl, M., Flammer, Y. et al.: Effects of homocysteine-lowering therapy on restenosis after percutaneeous coronary intervention for narrowings in small coronary arteries. Am. J. Cardiol., 2003, 91, s. 1265-1269.
46. Schnyder, G., Rouvinez G.: Total plasma homocysteine and restenosis after percutaneous coronary angioplasty: current evidence. Ann. Med., 2003, 35, s. 156-163.